Boxer Capital’s Eledon Pharmaceuticals ELDN Stock Holding History

Boxer Capital’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-18,021	Closed	-$201K	–	53
2019 Q3	$201K	Hold	18,021	–	–	0.01%	49
2019 Q2	$328K	Hold	18,021	–	–	0.03%	37
2019 Q1	$1.3M	Hold	18,021	–	–	0.15%	23
2018 Q4	$519K	Hold	18,021	–	–	0.06%	24
2018 Q3	$1.51M	Hold	18,021	–	–	0.17%	23
2018 Q2	$2.27M	Hold	18,021	–	–	0.26%	24
2018 Q1	$1.64M	Buy	+18,021	New	+$1.33M	0.17%	30

Other funds holding ELDN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boxer Capital's ELDN Position: Q4 2019 in Review

Boxer Capital sold out of Eledon Pharmaceuticals (ELDN) in Q4 2019, closing a stake of 18,021 shares — an estimated $201K sold.

Boxer Capital first reported a position in ELDN in Q1 2018 and held it in 7 quarters. The position peaked at $2.27M in Q2 2018. 10 funds tracked by Wall St. Rank hold ELDN as of Q4 2019.

Boxer Capital reported no remaining Eledon Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Boxer Capital sold 18,021 Eledon Pharmaceuticals shares in Q4 2019, an estimated $201K.
Boxer Capital first reported a position in Eledon Pharmaceuticals in Q1 2018 and held it in 7 quarters.
Boxer Capital's Eledon Pharmaceuticals position peaked at $2.27M in Q2 2018.
10 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2019.

Based on Boxer Capital's 13F filing for Q4 2019, filed 14 Feb 2020.